Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Sustainable Production Method Could Advance Plastics and Pharmaceuticals

By University of Texas | February 13, 2018

University of Texas engineers show off their school spirit by molding the new, sustainably produced plastic material into a Longhorn silhouette in Hal Alper’s lab. Credit: Cockrell School of Engineering, The University of Texas at Austin

A team of chemical engineers at The University of Texas at Austin has developed a new, cost-effective method for synthetically producing a biorenewable platform chemical called triacetic acid lactone (TAL) that can be used to produce innovative new drugs and sustainable plastics at an industrial scale, as described this week in Proceedings of the National Academy of Sciences.

Led by Hal Alper, professor in the McKetta Department of Chemical Engineering in the Cockrell School of Engineering, the team’s new method involves engineering the yeast Y. lipolytica to increase production of TAL, a polyketide, to levels that far exceed current bioproduction methods. This was accomplished by rewiring metabolism in the yeast through synthetic biology and genetic engineering. Ultimately, the research team increased production capacity tenfold, enabling polyketides to be mass-produced for incorporation into a variety of new applications in industry.

Polyketides are an important class of naturally derived molecules that can be used to make many useful products such as nutritional supplements, specialty polymers, pigments and pharmaceuticals. Currently, there are more than 20 drugs derived from polyketides on the market, including immunosuppressants, statins and antimicrobials.

Up to this point, synthetic production of polyketides has been constrained by technical challenges, limiting practical applications for consumer- and industry-based needs. In particular, most technologies have limited product yields resulting in difficult chemical synthesis and poor economics. The UT Austin team’s breakthrough could change that.

Using their new method, the researchers were able to purify TAL directly from a bioreactor to make a new plastic material that can be formed into a film and is seen to exhibit an orange hue and relative transparency.

“We hope to open up new product and industrial opportunities in the chemical and pharmaceutical spaces,” Alper said. “Our engineering efforts in TAL showcase that we can rewire metabolism to create renewable solutions to traditional chemical manufacturing.”

The UT Austin Office of Technology Commercialization has filed U.S. patent applications for the technology and is working to secure worldwide patents. The office is seeking commercial partners who have interest in improving the economics of polyketide production or creating new materials or products from polyketides.

“An important role for our institution, as one of the nation’s leading public research universities, is to move UT Austin’s research from the laboratory to useful products and services for the marketplace,” said Dan Sharp, director of the UT Austin Office of Technology Commercialization. “Research like this addresses that priority and provides society with innovative solutions that grow our economy and improve the quality of life.”

This work was funded by the Camille and Henry Dreyfus Foundation and the Welch Foundation.

SOURCE: University of Texas


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE